Table 1.
Participants’ Baseline and Demographic Data
| Characteristic | Stem cell group (n=41) | Control group (n=41) | p-value |
|---|---|---|---|
| Age, yr | 34.3 (21–44) | 32.7 (20–41) | 0.72 |
| Sex, male/female | 24/17 | 26/15 | 0.65 |
| Medical history of CD, yr | 7 (2–15) | 8 (3–14) | 0.66 |
| BMI, kg/m2 | 22.5±2.6 | 23.1±3.2 | 0.58 |
| Current smoker/smoking history | 2/10 | 1/8 | 0.55/0.59 |
| Montreal classification | |||
| Age at diagnosis, yr | 0.99 | ||
| A1: below 16 | 2 | 1 | |
| A2: between 17 and 40 | 38 | 40 | |
| A3: above 40 | 1 | 0 | |
| Location | 0.73 | ||
| L1: ileal | 14 | 17 | |
| L2: colonic | 18 | 14 | |
| L3: ileocolonic | 9 | 10 | |
| L4: isolated upper disease* | 6 | 9 | 0.39 |
| Behavior | 0.24 | ||
| B1: nonstricturing, nonpenetrating | 23 | 17 | |
| B2: stricturing | 10 | 14 | |
| B3: penetrating | 8 | 10 | |
| p: perianal disease modifier* | 6 | 7 | 0.76 |
| Operation history | 12 | 9 | 0.45 |
| CDAI | 281.5±75.2 | 293.2±68.4 | 0.48 |
| HBI | 12.7±3.2 | 11.9±3.5 | 0.55 |
| CDEIS | 9.2±1.5 | 8.7±2.3 | 0.63 |
| Steroid dosage, mg | 13.6±2.8 | 12.8±2.5 | 0.57 |
| Concomitant medication | |||
| AZA | 7 | 8 | 0.78 |
| MTX | 5 | 7 | 0.53 |
| 6MP | 6 | 10 | 0.27 |
| Antibiotics | 12 | 8 | 0.30 |
| Prior anti-TNF therapy | 13 | 9 | 0.32 |
| Infliximab | 4 | 3 | 0.69 |
| Adalimumab | 9 | 6 | 0.39 |
Data are presented as median (range) or mean±SD.
CD, Crohn’s disease; BMI, body mass index; CDAI, Crohn’s disease activity index; HBI, Harvey-Bradshaw index; CDEIS, Crohn’s disease endoscopic index of severity; AZA, azathioprine; MTX, methotrexate; 6MP, 6-mercaptopurine; TNF, tumor necrosis factor.
*
Indicates a modifier that can be added to other classifications when present as a concomitant symptom.